Evoke

Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team

Retrieved on: 
Tuesday, April 9, 2024
Data Analytics, General Health, Health, Marketing, Advertising, Communications, Professional Services, Business, Cooking, Growth, Learning, EVP, Disease, Marg, HIV, Steph, Diabetes, Nursing, SVP, KOL, BMS, Evoke, Overalls, Senior, Dog, Creativity, LTC, Multimedia, Tiff, EMT, Management

View the full release here: https://www.businesswire.com/news/home/20240408262170/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240408262170/en/
    Tiffany Marg & Steph Carman (Photo: Business Wire)
    Tiffany has over 20 years of experience in pharmaceutical marketing, building brands and executing campaigns.
  • In her previous role as SVP of Client Services, Tiffany was dedicated to building a first-class service team for Underscore’s clients, ensuring alignment between their ongoing business needs and goals and the execution of Underscore’s strategy and solutions.
  • Tiffany stated, “I am proud of the team we’ve built to lead our client engagements at Underscore and am excited for this next opportunity.
  • I originally came to Underscore because I was passionate about ensuring alignment between clients’ business objectives, brand and creative strategy, and media engagement strategy.

Trinity Hunt Announces Formation of Supreme Group and Appoints Tom Donnelly CEO

Retrieved on: 
Wednesday, March 20, 2024
Professional Services, Marketing, Health, Digital Marketing, Communications, Finance, General Health, Knowledge, MKG, Growth, Medicine, Court Square Capital Partners, Novo Holdings A/S, Donnelly (surname), Evoke, Advertising, Pharmaceutical industry

Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.

Key Points: 
  • Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.
  • “Tom’s extensive experience leading and growing healthcare marketing and communications businesses makes him the ideal leader for Supreme Group,” said Mike Steindorf, partner at Trinity Hunt.
  • “I am excited to join Supreme Group and look forward to making an impact in this dynamic and growing space,” said Donnelly.
  • “Already during my short time working with Trinity Hunt and the team at Supreme Optimization, we have made tremendous progress in building the Supreme Group platform.”

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Retrieved on: 
Wednesday, February 14, 2024
Attention, Suite, Telephone, Evoke, Fifth Avenue, Sale, Equity capital markets, Form, Series, Capital Group Companies, Form S-1, Security (finance), Metoclopramide, Prescription

"We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.

Key Points: 
  • "We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors," stated Evoke Pharma Chief Executive Officer Dave Gonyer.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Retrieved on: 
Friday, February 9, 2024
Equity capital markets, Suite, Sale, Form, Metoclopramide, Security (finance), Attention, Fifth Avenue, Capital Group Companies, Evoke, Telephone, Series

The combined price per share of common stock, Series A Warrant, Series B Warrant and Series C Warrant is $0.68, totaling $7.5 million initial gross proceeds to the Company.

Key Points: 
  • The combined price per share of common stock, Series A Warrant, Series B Warrant and Series C Warrant is $0.68, totaling $7.5 million initial gross proceeds to the Company.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

Evoke unveils simplified brand and structure: Inizio Evoke

Retrieved on: 
Monday, January 8, 2024
Professional corporation, HCP, International, Transformation, Access, Data communication, Health, Evoke, Patient, Thought, DTC, Advertising, Growth, Creativity, Automation, CX, Kyne, Online shopping

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Evoke, an Inizio company, today announces it has simplified its brand and enhanced its offerings to ensure clients receive the most effective solutions tailored to the dynamic healthcare landscape. With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access. As one integrated platform, Inizio Evoke now delivers a more advanced offering and more intuitive experience for its clients and people. It further connects global capabilities to deliver the best thinking and provide clients with best-in-industry work, creative, and innovative solutions.

Key Points: 
  • With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access.
  • "Building on our decades-long legacy of innovation, creativity, and impact in healthcare, our new unified brand reflects our commitment to our clients," said Reid Connolly, CEO of Inizio Evoke.
  • Evoke specialty agencies are now operating under the new Inizio Evoke brand as follows:
    Inizio Evoke: Combines the global marketing expertise of Evoke North America, Evoke Europe, and Evoke Mind+Matter UK to deliver full-service brand marketing, advertising, and creative capabilities that harness data-driven insights to deliver transformative impact across DTC, Patient, and HCP audiences.
  • Inizio Evoke Comms: Integrates the specialized experience from Evoke Canale, Evoke Galliard, and Evoke Kyne to deliver award-winning global health communications for clients across pharma, biopharma, biotech, and non-profit.

Evoke unveils simplified brand and structure: Inizio Evoke

Retrieved on: 
Monday, January 8, 2024
Professional corporation, HCP, International, Transformation, Access, Data communication, Health, Evoke, Patient, Thought, DTC, Advertising, Growth, Creativity, Automation, CX, Kyne, Online shopping

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Evoke, an Inizio company, today announces it has simplified its brand and enhanced its offerings to ensure clients receive the most effective solutions tailored to the dynamic healthcare landscape. With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access. As one integrated platform, Inizio Evoke now delivers a more advanced offering and more intuitive experience for its clients and people. It further connects global capabilities to deliver the best thinking and provide clients with best-in-industry work, creative, and innovative solutions.

Key Points: 
  • With this simplified brand ecosystem, the platform unites its specialty agencies and capabilities under a singular Inizio Evoke brand and core service areas in Marketing, Comms, Transformation, Media, and Access.
  • "Building on our decades-long legacy of innovation, creativity, and impact in healthcare, our new unified brand reflects our commitment to our clients," said Reid Connolly, CEO of Inizio Evoke.
  • Evoke specialty agencies are now operating under the new Inizio Evoke brand as follows:
    Inizio Evoke: Combines the global marketing expertise of Evoke North America, Evoke Europe, and Evoke Mind+Matter UK to deliver full-service brand marketing, advertising, and creative capabilities that harness data-driven insights to deliver transformative impact across DTC, Patient, and HCP audiences.
  • Inizio Evoke Comms: Integrates the specialized experience from Evoke Canale, Evoke Galliard, and Evoke Kyne to deliver award-winning global health communications for clients across pharma, biopharma, biotech, and non-profit.

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Retrieved on: 
Tuesday, November 14, 2023
Vomiting, Absorption, Evoke, Disease, Gastroparesis, Tablet, Patient, FDA, Metoclopramide, Extrapyramidal system, Patent, Diabetes, Pharmaceutical industry

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.

Key Points: 
  • SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.
  • 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.
  • This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others.
  • GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis.

First Member Driven Direct-to-Consumer Advertising Co-Op for Cannabis Announces 'TLC with Your THC' Fall Educational Advertising Campaign

Retrieved on: 
Tuesday, December 5, 2023
Safety, TLC, CBD, Evoke, Language, Cannabis, Ethics, Patient, Multimedia, Pharmacist, Health, MBA, Ocean Tomo, Environment, Drug

The first of its kind standards-based cooperative for the cannabis and hemp industry aims to ensure safety is a top priority for those celebrating the season with cannabis and CBD.

Key Points: 
  • The first of its kind standards-based cooperative for the cannabis and hemp industry aims to ensure safety is a top priority for those celebrating the season with cannabis and CBD.
  • Message headlines of the campaign include:
    Acannability™ is led by proven executives, informed by hands-on industry leaders, and guided by a team of renowned scientific and business advisors.
  • "The catalyst for creation of Acannability™ as the first-ever cannabis advertising cooperative was a gathering of cannabis license holders and hemp innovators" explains Acannability Co-founder James Malackowski.
  • The cooperative works to establish a trusted, standardized, labeling of ingredients/instructions and or provide online information about dosage, administration, and consumption.

Evoke Announces Appointment of Group President Cris Morton

Retrieved on: 
Monday, October 30, 2023
Health, HCP, Growth, AOR, Marketing, DTC, Management, Amici miei – Come tutto ebbe inizio, Evoke

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Evoke, an Inizio company and leading global life sciences brand, experience, and communications platform, announced today the appointment of Cris Morton as Group President, Marketing.

Key Points: 
  • NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Evoke, an Inizio company and leading global life sciences brand, experience, and communications platform, announced today the appointment of Cris Morton as Group President, Marketing.
  • "I am thrilled to have Cris join the leadership team at Evoke," said Reid Connolly, CEO & Founder of Evoke.
  • Cris joins Evoke most recently from Havas Health & You where he served as Group President for over 12 years and held numerous leadership roles prior with FCB Health and TBWA/World Health.
  • "I am so excited to be joining the Evoke team especially at this moment as there is real, palpable momentum," said Cris.

Evoke Announces Appointment of Group President Cris Morton

Retrieved on: 
Monday, October 30, 2023
Health, HCP, Growth, AOR, Marketing, DTC, Management, Amici miei – Come tutto ebbe inizio, Evoke

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Evoke, an Inizio company and leading global life sciences brand, experience, and communications platform, announced today the appointment of Cris Morton as Group President, Marketing.

Key Points: 
  • NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Evoke, an Inizio company and leading global life sciences brand, experience, and communications platform, announced today the appointment of Cris Morton as Group President, Marketing.
  • "I am thrilled to have Cris join the leadership team at Evoke," said Reid Connolly, CEO & Founder of Evoke.
  • Cris joins Evoke most recently from Havas Health & You where he served as Group President for over 12 years and held numerous leadership roles prior with FCB Health and TBWA/World Health.
  • "I am so excited to be joining the Evoke team especially at this moment as there is real, palpable momentum," said Cris.